These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multicenter Rullmann M; Brendel M; Schroeter ML; Saur D; Levin J; Perneczky RG; Tiepolt S; Patt M; Mueller A; Villemagne VL; Classen J; Stephens AW; Sabri O; Barthel H; On Behalf Of The German Imaging Initiative For Tauopathies Gii T Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327650 [TBL] [Abstract][Full Text] [Related]
8. Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease. Macedo AC; Durço DFPA; Tissot C; Therriault J; Vilela de Faria AO; Aumont É; Servaes S; Rahmouni N; Fernandez-Arias J; Wang YT; Lussier FZ; Bieger A; Zimmer ER; Pascoal TA; Gauthier S; Rosa-Neto P J Prev Alzheimers Dis; 2024; 11(2):414-421. PubMed ID: 38374747 [TBL] [Abstract][Full Text] [Related]
9. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940 [TBL] [Abstract][Full Text] [Related]
10. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ; Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897 [TBL] [Abstract][Full Text] [Related]
11. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework. Macedo AC; Tissot C; Therriault J; Servaes S; Wang YT; Fernandez-Arias J; Rahmouni N; Lussier FZ; Vermeiren M; Bezgin G; Vitali P; Ng KP; Zimmer ER; Guiot MC; Pascoal TA; Gauthier S; Rosa-Neto P J Nucl Med; 2023 Aug; 64(8):1171-1178. PubMed ID: 37321820 [TBL] [Abstract][Full Text] [Related]
12. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Biel D; Brendel M; Rubinski A; Buerger K; Janowitz D; Dichgans M; Franzmeier N; Alzheimers Res Ther; 2021 Aug; 13(1):137. PubMed ID: 34384484 [TBL] [Abstract][Full Text] [Related]
13. One-Year Longitudinal Changes in Tau Accumulation on [ Oh M; Oh SJ; Lee SJ; Oh JS; Seo SY; Ryu S; Roh JH; Lee JH; Kim JS J Nucl Med; 2024 Mar; 65(3):453-461. PubMed ID: 38302152 [TBL] [Abstract][Full Text] [Related]
14. Associations between quantitative [ Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512 [TBL] [Abstract][Full Text] [Related]
15. The spatial extent of tauopathy on [ Gérard T; Colmant L; Malotaux V; Salman Y; Huyghe L; Quenon L; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1662-1674. PubMed ID: 38228971 [TBL] [Abstract][Full Text] [Related]
16. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372 [TBL] [Abstract][Full Text] [Related]
17. Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals. Woo MS; Tissot C; Lantero-Rodriguez J; Snellman A; Therriault J; Rahmouni N; Macedo AC; Servaes S; Wang YT; Arias JF; Hosseini SA; Chamoun M; Lussier FZ; Benedet AL; Ashton NJ; Karikari TK; Triana-Baltzer G; Kolb HC; Stevenson J; Mayer C; Kobayashi E; Massarweh G; Friese MA; Pascoal TA; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P Alzheimers Dement; 2024 Feb; 20(2):1166-1174. PubMed ID: 37920945 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity. Pyun JM; Park YH; Youn YC; Kang MJ; Shim KH; Jang JW; You J; Nho K; Kim S; Transl Psychiatry; 2024 Feb; 14(1):88. PubMed ID: 38341444 [TBL] [Abstract][Full Text] [Related]
19. Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Guo Y; Huang YY; Shen XN; Chen SD; Hu H; Wang ZT; Tan L; Yu JT; Alzheimers Res Ther; 2021 May; 13(1):93. PubMed ID: 33947453 [TBL] [Abstract][Full Text] [Related]
20. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. Koychev I; Hofer M; Friedman N J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]